Human Metapneumovirus (HMPV) is not new — it was first identified in the Netherlands in 2001 — but it returned to Indian headlines in 2025 when cases spiked across Maharashtra, Karnataka, and Delhi. As of early 2026, Indian doctors are being asked the same questions by anxious patients. Here is a clear, fast clinical guide. What Is HMPV? HMPV belongs to the Paramyxoviridae family, the same group that includes RSV (Respiratory Syncytial Virus) and parainfluenza. It causes infections ranging from mild common-cold symptoms to severe pneumonia and bronchiolitis. There is currently no licensed vaccine or specific antiviral treatment. India's VRDLN (Virus Research and Diagnostic Laboratory Network) has been tracking HMPV since 2019. Between 2019 and 2024, positivity rates hovered around 3.2–3.3%, with children aged 1–2 years being the most affected group. Who Is Most at Risk? Children under 5 years (highest positivity in 1–2 age group) Elderly adults over 65 Immunocompromised patients — HIV, post-transplant, on chemotherapy Patients with chronic lung disease, asthma, or COPD Quick Clinical Guide: Human Metapneumovirus (HMPV) for Indian Clinics What is HMPV? Paramyxoviridae family virus (related to RSV, parainfluenza) Causes illness from mild URTI to severe bronchiolitis/pneumonia No licensed vaccine or specific antiviral yet VRDLN data (India, 2019–2024): ~3.2–3.3% positivity; highest in 1–2 year olds High‑Risk Groups Children <5 years (especially 1–2 years) Adults >65 years Immunocompromised (HIV, post‑transplant, chemotherapy, high‑dose steroids) Chronic lung disease, asthma, COPD Premature infants Typical Symptoms (URTI) Fever (mild to high‑grade) Dry or productive cough Rhinorrhoea / nasal blockage Sore throat Fatigue, malaise Red Flags / Severe Disease Wheeze, bronchospasm Tachypnoea, increased work of breathing Cyanosis (especially in children) Suspected pneumonia or bronchiolitis needing oxygen In SARI inpatients: median illness ~11 days; median stay ~7 days Diagnosis Preferred: RT‑PCR from nasopharyngeal swab (G or N gene targets) Rapid antigen tests: limited availability in India Multiplex respiratory PCR panels (tertiary centres) can detect HMPV along with influenza, RSV, SARS‑CoV‑2, etc. Differential Diagnosis Clinically indistinguishable from: Influenza A/B RSV Rhinovirus COVID‑19 Parainfluenza Do not assume based on symptoms alone. Test where available. Management (Supportive) Fever / pain: Paracetamol, adequate oral fluids Bronchospasm / wheeze: Nebulised salbutamol in children; inhaled bronchodilators as appropriate Severe respiratory distress: Oxygen therapy; consider ICU if persistent hypoxia, exhaustion, or haemodynamic instability Secondary bacterial infection: Start antibiotics only if clinical/lab evidence (focal consolidation, high procalcitonin, neutrophilic leukocytosis, etc.). Avoid prophylactic antibiotics. Antivirals: Ribavirin has limited evidence (mainly case reports in immunocompromised); not standard of care. When to Admit Admit if any of the following: SpO₂ <94% on room air Moderate–severe respiratory distress (nasal flaring, grunting, retractions, inability to speak/feed) Poor oral intake, dehydration (especially in infants/young children) High‑risk comorbidities with clinical deterioration or poor home support Infection Control in the Clinic/Hospital Droplet + contact precautions Mask all patients with respiratory symptoms Strict hand hygiene before/after every patient contact Cohort or separate suspected/confirmed HMPV from high‑risk patients Environmental cleaning: HMPV survives for hours on surfaces; disinfect high‑touch areas regularly Counselling Points for Patients / Parents Most healthy adults and children recover in 1–2 weeks with symptomatic care only. Explain that HMPV is a seasonal respiratory virus, not a “new COVID‑19”. Emphasise: Home isolation when febrile and coughing Hydration, fever control, monitoring of breathing When to return: fast breathing, chest indrawing, poor feeding, confusion, persistent high fever, or SpO₂ <94% if they have a pulse oximeter. Avoid demanding or prescribing antibiotics unless there is clear evidence of bacterial infection. Reporting HMPV is tracked under the Integrated Disease Surveillance Programme (IDSP). If you are a sentinel site or notice a cluster/outbreak pattern, report via standard IDSP channels. Key Takeaways for Indian Doctors Recognise and prioritise high‑risk patients. Use PCR for diagnosis where available; avoid empirical labelling. Provide supportive care, avoid unnecessary antibiotics and non‑evidence‑based antivirals. Admit based on objective severity criteria, not just test positivity. How Doctrust Can Help Your Clinic During HMPV Surges Paper records make it harder to track respiratory surges, follow up high‑risk patients, and audit antibiotic use. A digitised clinic workflow can: Auto‑generate structured HMPV/respiratory templates in prescriptions Maintain longitudinal digital records for recurrent wheeze/bronchiolitis and high‑risk patients Enable teleconsultation for stable follow‑ups and counselling Send automated reminders for review visits, pulse oximetry checks, and vaccination updates (e.g., influenza, pneumococcal) Support analytics on case load, admission referrals, and antibiotic prescribing patterns Doctrust offers: AI‑assisted prescription writing tailored to Indian practice Secure digital EMR for every patient Integrated teleconsultation and e‑prescriptions Automated follow‑up reminders and recall lists If HMPV and other respiratory infections are rising in your area, shifting off paper can reduce errors, improve continuity of care, and help you respond faster to surges. Visit www.doctrust.in to explore features and book a demo so your clinic can be fully digital before the next outbreak season.